Piper Jaffray Companies set a $49.00 price target on Pacira Pharmaceuticals (NASDAQ:PCRX) in a report published on Tuesday. The firm currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity lowered their price target on shares of Pacira Pharmaceuticals from $46.00 to $42.00 and set a hold rating for the company in a report on Tuesday, January 30th. Oppenheimer restated a hold rating on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. HC Wainwright restated a buy rating and issued a $52.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. JPMorgan Chase & Co. assumed coverage on shares of Pacira Pharmaceuticals in a report on Monday, December 18th. They issued a neutral rating and a $47.00 price objective for the company. Finally, Seaport Global Securities assumed coverage on shares of Pacira Pharmaceuticals in a report on Friday, January 19th. They issued a buy rating and a $50.00 price objective for the company. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $48.47.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $35.90 on Tuesday. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The company has a market cap of $1,460.00, a price-to-earnings ratio of -27.40 and a beta of 1.88.

In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief accounting officer now directly owns 23,455 shares in the company, valued at $938,200. The disclosure for this sale can be found here. Insiders sold a total of 40,075 shares of company stock worth $1,610,690 over the last ninety days. Insiders own 6.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in PCRX. Mesirow Financial Investment Management Equity Management purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter valued at about $14,671,000. Stonepine Capital Management LLC purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter valued at about $14,089,000. Epoch Investment Partners Inc. grew its position in Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock valued at $20,127,000 after purchasing an additional 354,728 shares during the last quarter. Vanguard Group Inc. grew its position in Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after purchasing an additional 211,982 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Pacira Pharmaceuticals by 36.2% during the 4th quarter. Renaissance Technologies LLC now owns 509,900 shares of the company’s stock valued at $23,277,000 after purchasing an additional 135,400 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals (PCRX) Given a $49.00 Price Target by Piper Jaffray Companies Analysts” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/02/14/pacira-pharmaceuticals-pcrx-given-a-49-00-price-target-by-piper-jaffray-companies-analysts.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.